Ionis Pharmaceuticals Files 8-K on Operations

Ticker: IONS · Form: 8-K · Filed: May 7, 2024 · CIK: 874015

Sentiment: neutral

Topics: operations, financials, sec-filing

Related Tickers: IONS

TL;DR

IONIS filed an 8-K. Standard ops and financials update.

AI Summary

On May 7, 2024, Ionis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or operational updates were detailed in the provided excerpt.

Why It Matters

This filing indicates a routine update on Ionis Pharmaceuticals' operational and financial status, which is important for investors to monitor company performance and compliance.

Risk Assessment

Risk Level: low — This filing is a standard operational and financial update, not indicating any immediate material changes or risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by Ionis Pharmaceuticals?

The primary purpose of this 8-K filing is to report on the company's Results of Operations and Financial Condition, as well as to provide Financial Statements and Exhibits.

What is the exact date of the report for Ionis Pharmaceuticals?

The exact date of the report is May 7, 2024.

In which state was Ionis Pharmaceuticals, Inc. incorporated?

Ionis Pharmaceuticals, Inc. was incorporated in Delaware.

What is the IRS Employer Identification Number for Ionis Pharmaceuticals?

The IRS Employer Identification Number for Ionis Pharmaceuticals is 33-0336973.

What is the business address and phone number listed for Ionis Pharmaceuticals?

The business address is 2855 Gazelle Court, Carlsbad, CA 92010, and the phone number is (760) 931-9200.

Filing Stats: 609 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-05-07 11:15:41

Filing Documents

02

Item 2.02 Results of Operations and Financial Condition. On May 7, 2024, Ionis Pharmaceuticals, Inc. (the " Company ") issued a press release announcing the Company's financial results for the quarter ended March 31, 2024. In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles (" GAAP "), the Company also discloses pro forma or non-GAAP results of operations, which are adjusted from GAAP to exclude non-cash compensation expense related to equity awards and the related tax effects. The Company is presenting pro forma information excluding non-cash compensation expense and the related tax effects because the Company believes it better enables financial statement users to assess and compare its historical performance and project its future operating results and cash flows. A copy of the release is furnished with this report as an exhibit pursuant to "Item 2.02. Results of Operations and Financial Condition" of Form 8-K in accordance with SEC Release Nos. 33-8216 and 34-47583. The information in this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the " Exchange Act ") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated May 7, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Ionis Pharmaceuticals, Inc. Dated: May 7, 2024 By: /s/ Patrick R. O'Neil Patrick R. O'Neil Executive Vice President, Chief Legal Officer and General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing